Overview Pediatric Arthritis Study of Certolizumab Pegol Status: Recruiting Trial end date: 2024-04-01 Target enrollment: Participant gender: Summary A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA). Phase: Phase 3 Details Lead Sponsor: UCB BIOSCIENCES GmbHCollaborator: PRA Health SciencesTreatments: Certolizumab Pegol